-
Mashup Score: 2
The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Preliminary Clinical Activity Observed With Paxalisib in R/R PCNSL - 6 month(s) ago
With over half of the patients enrolled in the phase 2 trial evaluating paxalisib in relapsed/refractory primary central nervous system lymphoma, some partial responses and stable disease have already been seen.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Part A of the phase 2 PROSPECT study, which is evaluating the efficacy and safety of tirabrutinib in patients with R/R primary central nervous system lymphoma has completed enrollment. #PCNSL #LYMSM https://t.co/6Or0IrYxyU https://t.co/2K8q0eS13Q